Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
Stopped The trial was discontinued due to sponsor's decision and not a consequence of any safety concern.
Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Interventions
Sponsor
Cellectis S.A.